The rejuvenating treatment market is drawing attention as one of the solutions for population aging, but there are few substantive outcomes, such as “passing phase 3 clinical trials,” a report said.
The Biotech Information Portal (BioIn) recently released a report, “Global anti-aging treatment market forecast for 2013,” analyzing the market for anti-aging drugs to prevent or slow cell and immunity aging.
According to the report, there will come a “silver tsunami,” which will likely more than triple the number of people aged 80 or older worldwide in 2050 compared to 2015. Notably, the older adults population will increase by four or more times in some Asian and Latin American countries,
As a result, the incidence of senile diseases is also growing. In 2020, 84 percent of Koreans aged 65 and older had one or more chronic diseases. Among those aged 75-79, 61.4 percent had two or more chronic diseases. The comparable rates rose to 66.2 percent in 80-84-year-olds and 73.1 percent in the over-85 group.
Suppose an approach could be found to prevent or delay the development of age-related diseases. In that case, it is expected to lead to the rapid growth of the anti-aging treatment market.
The report forecasted that the global anti-aging treatment market would grow by 17.5 percent annually, from $680 million in 2023 to $2.47 billion in 2031.
“Amid growing anxiety about aging, public interest in anti-aging products that slow the aging process is on the rise,” it said. “Besides, the characteristics of aging cells are identified, and aging-related genes and mechanisms of action are known, deepening the public’s understanding of the aging phenomenon.”
However, despite the huge potential of the market worth billions of dollars in solving chronic disease problems, it remains at a nascent stage due to difficulties in commercialization, the report pointed out.
Although many companies have developed chemical compounds that can solve chronic diseases and show results in preclinical trial stages, there are no treatments yet that have passed phase 3 clinical trials,” it added.
Although research is actively underway based on various aging control strategies related to aging, such as young blood transfusions, anti-aging factors in the blood, elimination of aging cells, multiple omics-based aging prediction and disease diagnosis, intestinal microorganisms, and longevity, there is still a lack of scientific evidence, it said.
The report also expressed concerns about the potential side effects of artificial manipulation of aging.
Noting that cell aging is one of the essential functioning factors, the report said, “When these factors are selectively manipulated, we don't know how they will affect the patient's health,” it said, calling for caution in analyzing their side effects.